drugset / Trial / NCT05471323
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
Phase 1
Unknown
36 enrolled
Guangdong Ruishun Biotech Co., Ltd
First Affiliated Hospital of Zhejiang University · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of RC1012 infusion in patients with relapsed or refractory Acute Myelocytic Leukemia (r/r AML).
Timeline
- Start
- 2021-01-14
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RC1012 | Cell therapy | 5e+07 cells/kg | — |
| Subject | RC1012 | Cell therapy | 1.5e+08 cells/kg | — |
| Subject | RC1012 | Cell therapy | 4.5e+08 cells/kg | — |